Companies / BOC Sciences / Eculizumab
BOC Sciences

Eculizumab | BOC Sciences

Eculizumab is a recombinant human IgG2/4_ monoclonal antibody used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Eculizumab acts as a terminal complement inhibitor that binds to the terminal complement component 5, or C5 and suppresses the complement cascade.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.